| ￥3500 | |
| Z05186-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Complement C5, His, Human at 2μg/ml (100μl/well) on the plate can bind AntiComplement C5 Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 112.5 kDa (α chain) and 73.29 (β chain) | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 110-114 kDa (α chain) and 69-73 (β chain) based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Complement component 5 (C5) is an essential factor of the defensive complement system in all vertebrates.C5 plays a major role in complement activation; C5 convertase cleaves C5 into the pro-inflammatory C5a, and C5b, the nidus for the formation of the lytic membrane attack complex. |
| Synonyms | Complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
